Who Paid My Doc
Subramaniam Seetharaman
Family Medicine Milwaukie, OR Medical Doctor
NPI 1598945131 CMS profile 892358
3033 Se Monroe St, Fl 2, Milwaukie, OR 97222
General payments
$6,707
Research payments
$17,920
Ownership & investment interest
$0
Research they led as principal investigator
$1,752,778
Through program year 2025, Subramaniam Seetharaman of Milwaukie, OR is reported in the CMS Open Payments database as having received $6,707 across 25 general payments and $17,920 in research payments paid to them. Separately, studies naming them as principal investigator received $1,752,778 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 98th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | Research | $119 | 2 | |
| 2024 | General | $94 | 1 | |
| 2024 | Research | $17,241 | 1 | |
| 2023 | General | $19 | 1 | |
| 2023 | Research | $560 | 1 | |
| 2022 | General | $14 | 1 | |
| 2020 | General | $5,735 | 13 | |
| 2019 | General | $845 | 9 |
Beside peers
- Subramaniam Seetharaman
- Family Medicine median
- Middle half of Family Medicine
- National median
In program year 2025, general payments to Subramaniam Seetharaman were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.
Show as a table
| Year | Subramaniam Seetharaman | Family Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $845 | $150 | $41–$543 | $163 |
| 2020 | $5,735 | $120 | $32–$415 | $114 |
| 2021 | $0 | $137 | $35–$551 | $132 |
| 2022 | $14 | $137 | $37–$512 | $149 |
| 2023 | $19 | $149 | $42–$545 | $160 |
| 2024 | $94 | $156 | $44–$560 | $164 |
| 2025 | $0 | $155 | $45–$549 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 107 drugsPart D claims
4,466
Drug cost
$400,017
Branded share of claims
20.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 87 | $100,624 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 75 | $62,024 | |
| Ozempic Semaglutide | Brand | 35 | $45,042 | |
| Xarelto Rivaroxaban | Brand | 20 | $27,758 | |
| Rybelsus Semaglutide | Brand | 18 | $21,754 | |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | Brand | 14 | $17,279 | |
| Trulicity Dulaglutide | Brand | 14 | $13,594 | |
| Mounjaro Tirzepatide | Brand | 13 | $13,240 | |
| Farxiga Dapagliflozin Propanediol | Brand | 12 | $8,554 | |
| Atorvastatin Calcium | Generic | 432 | $5,779 |
The 10 drugs with the highest cost, of 107 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 71 billing codesPaid by Medicare
$23,924
Medicare patients
69
Services billed
845
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 70% | |
| Depression | 39% | |
| Chronic kidney disease | 38% | |
| Heart failure | 32% | |
| Arthritis | 32% | |
| Atrial fibrillation | 28% | |
| Diabetes | 25% | |
| Ischemic heart disease | 22% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Pcv20 vaccine im 90677 | Office | 11 | 11 | $3,204 |
| Vaccine for influenza for injection into muscle 90662 | Office | 18 | 18 | $1,453 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
29 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Family Medicine in Oregon
Related records
Family Medicine in Oregon
Practitioners in the same specialty and state, ranked by reported value.
All Family Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Oregon
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.